| Name | Title | Contact Details |
|---|
Cellenkos is an early stage clinical biotechnology company that focuses on cord blood-derived T-regulatory cellular therapies for the treatment of autoimmune diseases and inflammatory conditions. Cellenkos is founded on the technologies arising from the laboratory investigations of Simrit Parmar, M.D. Cellenkos` lead product CK0801 delivers clinically meaningful doses of allogeneic cord blood T-regulatory cells to overcome immune dysfunction.
Telesta Therapeutics is a biopharmaceutical company focused on the development, manufacturing and commercialization of transformative human therapeutics. Our main focus is on novel medicines that address major unmet medical needs, particularly in oncology. Our anchor product, MCNA, has completed a Phase III pivotal study in patients with non-muscle invasive bladder cancer that have failed the first line therapy, bacillus Calmette-Guérin (BCG). Telesta submitted a Biologics Licensing Application (BLA) for MCNA with the U.S. FDA on June 29, 2015 and is seeking, upon marketing approval in the U.S., to make MCNA available for patients and their physicians. Our ultimate goal is to transform the treatment landscape and prolong and improve the lives of those affected by bladder cancer, one of the most common types of cancers today.
uBiome is the leading microbial genomics company. We are pioneering a new era of microbiome-based precision medicine. We allow doctors, patients, and citizen scientists to learn about the human microbiome with unprecedented accuracy and speed.
We offer a unique suite of solutions, with a unique perspective on clinical research development. We focus on bringing together best-in-class science, technology and service to drive superior clinical outcome results for our clients and for their patients. Increasing the Power of Clinical Research Data.
USAID is a Washington, DC-based company in the Healthcare, Pharmaceuticals, & Biotech sector.